Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 3/20 | 0.79 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.79 |
| ▸ | PLAU | P00749 | 5/20 | 0.54 |
| ▸ | PLG | P00747 | 2/20 | 0.54 |
| ▸ | PLAT | P00750 | 2/20 | 0.54 |
| ▸ | KLK1 | P06870 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 9/20 | 0.49 |
| ▸ | F10 | P00742 | 8/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stilbamidine SCHEMBL208655 | 0.89 | PRMT1 (1.00) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| Stilbamidine SCHEMBL889782 | 0.89 | PRMT1 (1.00) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL2517134 | 0.89 | ALDH1A1 (0.68) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL2517133 | 0.89 | ALDH1A1 (0.68) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL2521141 | 0.88 | ALDH1A1 (0.61) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL2521139 | 0.88 | ALDH1A1 (0.61) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| Stilbamidine SCHEMBL3932459 | 0.87 | PRMT1 (0.95) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| Stilbamidine SCHEMBL871695 | 0.85 | PRMT1 (0.91) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL2520060 | 0.84 | ALDH1A1 (0.73) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 | |
| SCHEMBL2520059 | 0.84 | ALDH1A1 (0.73) | PRMT1PRMT5ALDH1A1HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861564-B2 | Valeric acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT, LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-9782335-B2 | Malic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160303016-A1 | Valeric Acid Esters Of Resveratrol And Cosmetic Compositions | ELC MAN LLC (US) | 2016-10-20 | — | — | US | disclosed |
| EP-2445511-B1 | SKIN REPAIR COMPOSITIONS COMPRISING CIRCADIAN GENE ACTIVATORS AND A SYNERGISTIC COMBINATION OF SIRT1 GENE ACTIVATORS | ELC MAN LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160229791-A1 | Malic Acid Esters Of Resveratrol And Cosmetic Compositions | ELC MAN LLC (US) | 2016-08-11 | — | — | US | disclosed |
| US-9358194-B2 | Succinic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9295621-B2 | Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant | ELC MANAGEMENT LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160038389-A1 | Succinic Acid Esters Of Resveratrol And Cosmetic Compositions | ELC MAN LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9180316-B2 | Butyric acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9162083-B2 | Linoleic and Linolenic acid esters of resveratrol and cosmetic compositions | ELC MANAGEMENT LLC (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2185128-A1 | COSMETIC COMPOSITIONS CONTAINING RESVERATROL DERIVATIVES | ELC Management LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100080845-A1 | Cosmetic Methods And Compositions For Repairing Human Skin | MAES DANIEL H | 2010-04-01 | — | — | US | disclosed |
| US-20100028317-A1 | Skin Repair Compositions Comprising Circadian Gene Activators And A Synergistic Combination Of Sirt1 Gene Activators | ELC MANAGEMENT LLC | 2010-02-04 | — | — | US | disclosed |
| US-20090047309-A1 | COSMETIC METHODS AND COMPOSITIONS FOR REPAIRING HUMAN SKIN | ELC MANAGEMENT LLC | 2009-02-19 | — | — | US | disclosed |
| US-20090035243-A1 | Anhydrous Cosmetic Compositions Containing Resveratrol Derivatives | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035240-A1 | Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035242-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Linear Or Branched Silicone | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
| WO-2009017866-A1 | COSMETIC COMPOSITIONS CONTAINING RESVERATROL DERIVATIVES | ELC MANAGEMENT LLC (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090035237-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035236-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent | ELC MANAGEMENT LLC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035243-A1 | Anhydrous Cosmetic Compositions Containing Resveratrol Derivatives | RB1, SIRT1, EP300 | PRMT1 1104/4885PRMT5 1488/4885ALDH1A1 608/4885 |
| US-20090035242-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Linear Or Branched Silicone | SQLE, SMURF1, PIK3R1 | PRMT1 787/4885PRMT5 1101/4885ALDH1A1 3102/4885 |
| US-20090047309-A1 | COSMETIC METHODS AND COMPOSITIONS FOR REPAIRING HUMAN SKIN | CUTA, ERCC1, OGG1 | PRMT1 264/4885PRMT5 343/4885ALDH1A1 527/4885 |
| US-20100028317-A1 | Skin Repair Compositions Comprising Circadian Gene Activators And A Synergistic Combination Of Sirt1 Gene Activators | CRY1, PER2, SIRT1 | PRMT1 69/4885PRMT5 822/4885ALDH1A1 2290/4885 |
| US-20160303016-A1 | Valeric Acid Esters Of Resveratrol And Cosmetic Compositions | CUTA, SUV39H1, RARA | PRMT1 1486/4885PRMT5 1778/4885ALDH1A1 717/4885 |
| US-20090035237-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant | SMURF1, CUTA, SMURF2 | PRMT1 1048/4885PRMT5 1614/4885ALDH1A1 3004/4885 |
| US-20090035236-A1 | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent | CUTA, LRAT, RARA | PRMT1 1619/4885PRMT5 2571/4885ALDH1A1 2717/4885 |
| US-20090035240-A1 | Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent | SMARCC1, RARG, RARA | PRMT1 335/4885PRMT5 852/4885ALDH1A1 2613/4885 |
| US-20100080845-A1 | Cosmetic Methods And Compositions For Repairing Human Skin | CUTA, ERCC1, OGG1 | PRMT1 264/4885PRMT5 343/4885ALDH1A1 527/4885 |
| US-20160229791-A1 | Malic Acid Esters Of Resveratrol And Cosmetic Compositions | ME1, ME2, ME3 | PRMT1 1684/4885PRMT5 2172/4885ALDH1A1 295/4885 |
| US-20160038389-A1 | Succinic Acid Esters Of Resveratrol And Cosmetic Compositions | SUCNR1, SIRT1, SUCLA2 | PRMT1 1368/4885PRMT5 1594/4885ALDH1A1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.